Details, Fiction and Ponsegromab
All enrolled individuals who gained at the least one dose of zosuquidar or placebo all through induction ended up monitored for the event of adverse functions (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse gatherings were being connected to the period of prolonged and considerable myelosuppression as is anticipated with i